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Abstract
Background: The dose distribution to the rectum, delineated as solid organ, rectal wall and rectal
surface, in 3D conformal (3D-CRT) and intensity-modulated radiotherapy treatment (IMRT)
planning for localized prostate cancer was evaluated.
Materials and methods: In a retrospective planning study 3-field, 4-field and IMRT treatment
plans were analyzed for ten patients with localized prostate cancer. The dose to the rectum was
evaluated based on dose-volume histograms of 1) the entire rectal volume (DVH) 2) manually
delineated rectal wall (DWH) 3) rectal wall with 3 mm wall thickness (DWH3) 4) and the rectal
surface (DSH). The influence of the rectal filling and of the seminal vesicles' anatomy on these dose
parameters was investigated. A literature review of the dose-volume relationship for late rectal
toxicity was conducted.
Results: In 3D-CRT (3-field and 4-field) the dose parameters differed most in the mid-dose region:
the DWH showed significantly lower doses to the rectum (8.7% ± 4.2%) compared to the DWH3
and the DSH. In IMRT the differences between dose parameters were larger in comparison with
3D-CRT. Differences were statistically significant between DVH and all other dose parameters and
between DWH and DSH. Mean doses were increased by 23.6% ± 8.7% in the DSH compared to
the DVH in the mid-dose region. Furthermore, both the rectal filling and the anatomy of the
seminal vesicles influenced the relationship between the dose parameters: a significant correlation
of the difference between DVH and DWH and the rectal volume was seen in IMRT treatment.
Discussion: The method of delineating the rectum significantly influenced the dose representation
in the dose-volume histogram. This effect was pronounced in IMRT treatment planning compared
to 3D-CRT. For integration of dose-volume parameters from the literature into clinical practice
these results have to be considered.
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Background
Dose escalation has been effective in radiotherapy treat-
ment of localized prostate cancer. Especially intermediate
risk patients benefit from doses higher than 70Gy,
whether low and high risk patients do so is controversial
[1].
Late rectal toxicity, in particular late rectal bleeding,
turned out to be the limiting factor in dose escalation [2].
The Patterns of Care Study stated that the incidence of
severe rectal and bladder complications almost doubled
when dose levels were increased beyond 70Gy with con-
ventional treatment [3]. Three dimensional conformal
radiotherapy (3D-CRT) in comparison to conventional
radiotherapy resulted in lower rates of late rectal toxicity
[4] and allowed the safe administration of doses up to
80Gy. Intensity-modulated radiotherapy (IMRT) has been
indicated to be beneficial in comparison with 3D-CRT
and made further dose escalation to 86.4Gy possible [5].
The improvements from conventional RT to 3D-CRT and
from 3D-CRT to IMRT are due to more conformal dose
distributions with the high dose region confined to the
target volume and sparing of organs-at-risk [6,7]. The cor-
relation between the volume of the rectum within the
high dose region and the risk for late rectal toxicity sug-
gested a dose volume effect [8].
Dose-volume histograms (DVH) are widely used to evalu-
ate treatment plans and to estimate the risk for toxicity.
For solid organs like most tumors, liver or parotid gland
the DVH is based on the volume encompassed by the
outer contour of the organ. For "hollow" organs like the
rectum or bladder, the use of the DVH is controversial as
this implicates that rectum and bladder are solid organs.
From a radiobiological point of view the rectal wall with-
out its filling defines the critical structure. The content of
the hollow organ is irrelevant in terms of risk of complica-
tion. Therefore dose-wall histogram (DWH) and dose-sur-
face histogram (DSH) have been suggested to describe the
dose to hollow organs in a more appropriate way.
Whereas DVH and DWH calculate dose distributions to
3D volumes (entire rectal volume and rectal wall respec-
tively) DSH calculates dose distributions to 2D surfaces,
e.g. the outer contour of the rectal wall.
This study compared and analyzed the dose distribution
of the rectal DVH, DWH and DSH in 3D-CRT and IMRT
treatment planning for prostate cancer. A literature review
of the association of these dose parameters with late rectal
toxicity was conducted.
Materials and methods
This retrospective planning study included ten consecu-
tive patients treated for localized prostate cancer at the
Department of Radiation Oncology of the University of
Wuerzburg, Germany, between August 2003 and Novem-
ber 2003.
A spiral planning computed tomography (CT) scan was
acquired in the supine position. Slice thickness was 5 mm.
Patients were advised to have an empty bowel and a full
bladder. A full bladder was advised to keep larger parts of
the bladder outside the treatment fields. Simultaneously,
a distended rectum has been demonstrated to be not
reproducible during the total time of treatment [9].
Patients with a distended rectum in the planning CT
received a second CT study in the first or second week of
treatment. If the rectal filling was significantly smaller, a
new treatment plan based on the second planning CT was
generated.
Oncentra™ Treatment Planning (OTP) Version 1.3
(Nucletron, Veenendaal, Netherlands), now Masterplan™,
was utilized for treatment planning.
The clinical target volume (CTV) encompassed the pros-
tate gland and seminal vesicles to simulate treatment
plans with high risk of vesicle involvement. This target
volume concept was used because IMRT is particularly
beneficial for concave targets wrapped around organs-at-
risk (OAR) [10]. The planning target volume 1 (PTV 1)
was generated with a 3D margin of 5 mm around the GTV.
PTV 1 was not allowed to overlap with the rectum. PTV 2
was generated by defining a 3D margin of 10 mm around
the CTV but only 7 mm in posterior direction.
The bladder (as a solid organ) and both femoral heads
were defined as OARs. The rectum was contoured in four
different ways: 1) rectal wall based on manual delineation
of the inner and outer contour of the rectal wall 2) rectal
wall based on manual delineation of the outer contour of
the rectal wall and automatic calculation the inner con-
tour using a 3 mm margin [11]3) entire rectal volume
including the rectal wall and the rectal lumen 4) rectal sur-
face as the outer contour of the rectal wall. For all four
approaches the rectum was confined to 1 cm above to 1
cm below PTV 2 in superior-inferior direction. Therefore,
the delineated OAR rectum was different from the ana-
tomical anal canal and rectum as the most superior and
inferior parts were not included into the OAR. Anal canal
and rectum were not delineated as different OARs to make
the analysis and presentation of results more straight-for-
ward [12].
Treatment was planned for a Siemens PRIMUS™ linear
accelerator with 6 MV and 18 MV photon energy and a
multi-leaf collimator with 1 cm leaf width. The isocenter
was placed in the geometrical center of PTV 2. Two 3D-
CRT treatment plans were generated for each patient withRadiation Oncology 2006, 1:34 http://www.ro-journal.com/content/1/1/34
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a prescription dose of 70Gy to PTV 2 according to ICRU
50. Three-field plans with gantry angles of 0° (6 MV),
100° (18 MV) and 260° (18 MV) and four-field plans
with gantry angles of 0° (6 MV), 90° (18 MV), 180° (18
MV) and 270° (18 MV) were generated.
A third treatment plan with step-and-shoot IMRT was gen-
erated for each patient using optimization objectives
listed in Table 1. A simultaneous-integrated boost (SIB)
[10] concept with a prescription dose of 66Gy to PTV 2
and a prescription dose of 73Gy to PTV 1 in 33 fractions
was applied. Seven beams with 6 MV photon energy were
used; the isocentre was placed in the centre of the PTV2.
Five intensity levels were allowed for the optimization
with a minimum segment size of 2 cm2 and a maximum
of 10 segments per beam.
After plan generation the dose distribution was calculated
for targets and OARs of each treatment plan. For the rec-
tum the dose distribution to the manually delineated rec-
tal wall (DWH), to the semi-automatic delineated rectal
wall with 3 mm wall thickness (DWH3) and to the solid
rectum including the lumen (DVH) were calculated. The
dose distribution to the outer surface of the rectal wall
(DSH) was calculated using the CERR software developed
at Washington University in St. Louis [13]. Dx (Gy)
denotes the minimal dose (Gy) delivered to x volume per-
cent (x area percent for the DSH) of the evaluated volume-
of-interest (VOI).
Dose parameters were compared using student's t-test for
matched pairs. The Spearman's rank correlation was uti-
lized to test the correlation between pairs of values. For
statistical analysis Statistica 6.0 (Statsoft, Tulsa, USA) was
utilized. Differences were considered significant for p <
0.05.
Results
The three-field treatment plans compared with the four-
field plans resulted in significantly decreased doses to the
rectum in the low dose region D70 and D90. The relation-
ship between rectal DWH3, DWH, DVH and DSH was not
different between the three-field and the four-field plans.
Therefore, only results of the 3-field plans are reported in
the following and referred to as 3D-CRT in comparison to
results from the IMRT treatment plans.
The relationship between DWH3, DWH, DVH and DSH in
3D-CRT treatment planning is shown in Figure 1a. In the
high-dose region D5 to D20 an almost identical dose dis-
tribution to the rectum was shown by all four approaches.
In the mid-dose region D30 to D50 the doses displayed in
the DWH were significantly lower compared to doses in
the DSH and the DWH3: mean difference of 8.7% ± 4.2%
(mean ± SD). In the low-dose region of D70 and D90 the
DVH showed significantly higher dose of 6.8% ± 2.2%.
Correlation between corresponding dose parameters was
investigated by the nonparametric Spearman's rank test. A
highly significant linear correlation between pairs of
DWH3, DWH, DVH and DSH parameters was shown. Best
correlation was seen between DSH and DWH3  (R2  =
0.996), worst correlation between DVH and DWH (R2 =
0.939). The slope of linear fit lines ranged between 0.997
(DSH and DWH3) and 1.03 (DVH vs. DWH3).
Comparing 3D-CRT with IMRT treatment plans, more
pronounced differences between dose parameters were
seen for the latter (Fig 1b). In IMRT the differences were
Table 1: IMRT optimization objectives for OTP planning system
Organs-at-risk
Full Volume Dose (Gy) Max. Dose (Gy) Over Dose Volume (%) Limit Dose (Gy)
B l a d d e r 2 35 02 37 5
Right femoral head 27 41 9 50
Left femoral head 27 41 9 50
Rectum 23 50 21 73
Target volumes
Min. Dose (Gy) Prescription Dose (Gy) Under Dose (%) Limit Dose (Gy)
PTV 1 68 73 5 81
PTV 2 61 66 5 81
The nomenclature of the OTP TPS was used for description of dose volume objectives: For organs-at-risk: the minimum dose should be lower 
than "full volume dose"; "maximum dose" and "over dose volume" defines one DVH objective; "limit dose" is the maximum dose;
For targets: "Under dose (%)" is the volume (%) that is allowed receiving less than the prescription dose; "limit dose" is the maximum dose;Radiation Oncology 2006, 1:34 http://www.ro-journal.com/content/1/1/34
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statistically significant between DVH and all other dose
parameters, between DWH and DSH but not between
DWH and DWH3 and between DSH and DWH3. In the
high-, mid- and low-dose region the DSH showed signifi-
cantly higher doses to the rectum compared to the DVH.
Doses in the DSH were increased by 23.6% ± 8.7% com-
pared to the DVH in the mid-dose region; differences were
smaller in the high-dose region (9.2% ± 6.6%) and in the
low-dose region (6.2% ± 3.9%). The DWH showed
decreased doses compared with the DWH3 in all dose
regions.
In Fig. 2 the corresponding results of DWH3, DWH, DVH
and DSH were plotted and linear fit lines were calculated.
In general correlation between dose parameters was worse
in IMRT plans compared to 3D-CRT plans. Best correla-
tion was seen between DSH and DWH3 (R2 = 0.994) and
worst correlation between DSH and DVH (R2 = 0.930);
the slope of linear fit lines ranged between 1.01 (DWH vs.
DWH3) and 1.11 (DVH vs. DSH).
The influence of the rectal volume, the degree of rectal fill-
ing, on the relationship between the dose parameters was
investigated. Patients were equally divided into two sub-
groups according to the rectal volume.
In 3D-CRT treatment planning, no significant difference
was seen between DWH3, DVH and DSH for patients with
small rectal volumes (n = 5). For patients with a distended
rectum (n = 5) DSH and DWH showed identical results
but DVH showed significantly lower dose to the rectum in
the mid-dose region by 6.3% ± 7.2%. In the IMRT treat-
ment plans the influence of the rectal volume on the rela-
tionship between dose parameters was different. The
order of the dose distribution to the rectum was not differ-
ent between the sub-groups: DSH > DWH3 > DWH >
DVH. However, differences between dose parameters
were larger in the sub-group with a distended rectum. In
the mid-dose region the difference between DVH and
DWH was 7.5% ± 3.9% and 19.1% ± 4.9% in the sub-
group with small rectal volumes and with a distended rec-
tum, respectively. A statistical significant correlation (r =
0.81) between the rectal volume and the difference
between DVH and DWH was observed (Fig 3).
Furthermore, the influence of the anatomy of the seminal
vesicles on the relationship between the dose parameters
was tested. Two sub-groups were generated with five
patients each. The criterion was how far the seminal vesi-
cles were wrapped around the rectum.
In the 3D-CRT plans a significant difference between
DSH/DWH3 vs. DVH was seen for patients with the semi-
nal vesicles confined to the anterior rectal wall. With the
seminal vesicles wrapped around the rectum no difference
between DSH, DWH3 and DVH was found. Contrary, in
the IMRT treatment plans the anatomy of the seminal ves-
icles influenced the relationship between the dose param-
eters only marginally.
Dose distribution to the rectum was compared between
IMRT and 3D-CRT treatment. Depending on the way of
contouring the rectum the benefit of IMRT in sparing the
rectum was different (Fig. 4). Comparing IMRT and 3D-
CRT the IMRT technique resulted in 23% ± 15% decreased
doses to the rectal DVH in the mid dose region. Based on
DWH3 the benefit of the IMRT technique was 11% ± 11%
and based on DSH the benefit was reduced to 7% ± 10%.
Discussion
Reducing rectal toxicity represents a major challenge in
radiotherapy treatment planning for prostate cancer.
Treatment with escalated doses was shown to result in
improved rates of local control [14,15] but simultane-
ously higher doses to the rectum were found to be corre-
lated with increased rates of late rectal toxicity. Reliable
tools in treatment planning for estimating the risk of tox-
icity are therefore essential. The dose-volume histogram is
Dose-volume histogram of the rectum (averaged over all n =  10 patients) based on DWH3, DWH, DVH and DSH in Fig  1a) 3D-CRT and in Fig 1b) IMRT treatment planning Figure 1
Dose-volume histogram of the rectum (averaged over all n = 
10 patients) based on DWH3, DWH, DVH and DSH in Fig 
1a) 3D-CRT and in Fig 1b) IMRT treatment planning.
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Correlation between dose parameters in IMRT treatment planning Figure 2
Correlation between dose parameters in IMRT treatment planning. S (slope of linear fit line).Radiation Oncology 2006, 1:34 http://www.ro-journal.com/content/1/1/34
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a common tool to express the dose that is delivered to tar-
gets and OARs. Though dose-volume histograms do not
provide spatial information, i.e. the location of the high-
and low-dose regions ("hot" and "cold" spots) inside the
volume of interest, multiple studies have shown correla-
tion between dose-volume-histogram parameters and rec-
tal toxicity. In table 2 a literature review about these
studies is given.
However, the transfer of the results from table 2 into clin-
ical practice is complicated by the different way of con-
touring the rectum, different toxicity endpoints and
different classifications of rectal toxicity in the literature.
Within this retrospective planning study it was demon-
strated that the method of contouring the rectum signifi-
cantly influenced the "dose to the rectum" represented in
the dose-volume histogram. In general, delineation of the
rectal volume as a solid organ underestimated the expo-
sure of the rectum compared to delineation of the rectal
surface or the rectal wall. The differences were larger in
IMRT treatment planning compared to 3D-CRT. For one
single patient the dose to the rectum in the mid-dose
region was 35% higher in the DSH compared to the DVH.
The rectum was delineated from 1 cm superior to 1 cm
inferior the PTV. The delineated OAR rectum constituted
a fairly constant fraction of the anatomical anus/rectum
averaged over all patients (73% ± 4%). Portions of the rec-
tum outside the beam, receiving very low doses, were
therefore excluded from analysis. Differences between
dose parameters would have been smaller if the complete
anatomical anus and rectum would have been contoured.
It was also demonstrated that there was no constant rela-
tionship between dose parameters DWH3, DWH, DVH
and DSH for all patients. Both the rectal volume, the
degree of the rectal filling, and the anatomy of the seminal
vesicles were shown to be relevant. The pattern how these
anatomic characteristics influenced the relationship
between DWH3, DWH, DVH and DSH was different in
Comparison of 3-field (3F), 4-field (4F) and IMRT treatment  plans with the rectal dose based on the DVH (Fig 4a), the  DWH3 (Fig 4b) and the DSH (Fig 4c) Figure 4
Comparison of 3-field (3F), 4-field (4F) and IMRT treatment 
plans with the rectal dose based on the DVH (Fig 4a), the 
DWH3 (Fig 4b) and the DSH (Fig 4c).
0
10
20
30
40
50
60
70
80
90
100
0 1 02 03 04 05 06 07 08 0
Dose (Gy)
V
o
l
u
m
e
(
%
)
4F
3F
IMRT
0
10
20
30
40
50
60
70
80
90
100
0 1 02 03 04 05 06 07 08 0
Dose (Gy)
V
o
l
u
m
e
(
%
)
4F
3F
IMRT
0
10
20
30
40
50
60
70
80
90
100
0 1 02 03 04 05 06 07 08 0
Dose (Gy)
V
o
l
u
m
e
(
%
)
4F
3F
IMRT
Correlation of rectal volume and relative difference between  rectal DVH and DWH in IMRT treatment planning of pros- tate cancer Figure 3
Correlation of rectal volume and relative difference between 
rectal DVH and DWH in IMRT treatment planning of pros-
tate cancer.R
a
d
i
a
t
i
o
n
 
O
n
c
o
l
o
g
y
 
2
0
0
6
,
 
1
:
3
4
h
t
t
p
:
/
/
w
w
w
.
r
o
-
j
o
u
r
n
a
l
.
c
o
m
/
c
o
n
t
e
n
t
/
1
/
1
/
3
4
P
a
g
e
 
7
 
o
f
 
1
1
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 2: Literature review of dose-volume relationship for late rectal bleeding in radiotherapy of prostate cancer
Author Patients Follow up Persription 
Doses
Treatment 
technique
Classification 
of toxicity
Endpoint Events Dosimetric 
parameter
Rectum delineation Results
Hartford 1996 [29] 41 Minimum 4 
years
50.4Gy 
25.2CGE
4 field Perineal 
proton boost
RTOG ≥ Grad I 
rectal 
bleeding
14 DWH ant. 
RW
From superior limit of 
anus to 2 cm superior to 
prostate
Cut-off:
Continuously between 60Gy to 70% 
and 75Gy to 30%
Boersma 1998 [30] 130 Median 24 
months
70 – 76Gy 3 field 3D-CRT SOMA/LENT 
and RTOG/
EORTC
≥ Grad III 
rectal 
bleeding
2 DWH 15 mm caudal to the 
apex of the prostate to 
boarder to sigmoid
Cut-off:
≥ 65Gy to >40%
≥ 70Gy to >30%
≥ 75Gy to >5%
(no correlation for grade I/II rectal 
bleeding)
Storey 2000 [31] 189 Minimum 2 
years
70Gy 78Gy 4 field box 4 
field box, 6 field 
3D-CRT boost
Modified 
RTOG
≥ Grad II 
late rectal 
toxicity
28 DVH Rectum included within 
11 cm of initial APPA 
field
For patients treated to 78Gy:
Cut-off:
≥ 70Gy to >25%
Jackson 2001 [32] 451 Minimum 
30 months
70.2Gy 
75.6Gy
6 field 
arrangement 
3D-CRT
RTOG ≥ Grad III 
late rectal 
bleeding
49 DWH below sigmoid flexure to 
above anal verge
Correlation with:
# area under the average percent 
volume DWH
# Exposure to ~62% and to ~102% of 
prescription dose
Fenwick 2001 [33] 79 Minimum 2 
years
60 – 64Gy 3 field
• 3D-CRT
• Conventional
RTOG Grade I – 
III rectal 
bleeding
? DSH up to level of 
rectosigmoid junction
Correlation with:
% of RS exposed to > 57Gy
Wachter 2001 [34] 109 Median 30 
months
66Gy 4 field 3D-CRT EORTC/
RTOG
Grade II 
rectal 
bleeding
15 DVH From lower to upper 
boarder of 4 field
Cut-off:
≥ 60Gy to >57%
Kupelian 2002 [35] 128 Median 24 
months
78Gy 70Gy 4 field (42Gy) 6 
field boost 
(36Gy): 3D-CRT 
IMRT (SD 
2.5Gy)
RTOG Grade I – 
III rectal 
bleeding
9 DVH From 1 cm above to 1 
cm below the target
Cut-off:
Absolute rectal volume:
≥ 78Gy to >15 cm3
Huang 2002 [36] 163 Median 62 
months
74 – 78Gy 4 field 
conventional 
(46Gy) 6 field 
boost 3D-CRT
Modified 
RTOG
≥ Grad II 
late rectal 
toxicity
38 DVH 11 cm in length starting 
at 2 cm below the 
inferiormost aspect of 
the ischial tuberosities
Cut-off:
V60 below 40%
V70 below 25%
V75.6 below 15%
V78 below 5%R
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Fiorino 2003 [37] 245 Median 2 
years
70 – 78Gy 3 to 4 field 3D-
CRT
Modified 
RTOG
Grade II – 
III rectal 
bleeding
23 DVH Above anal verge to 
sigmoid
Cut-off:
V50 below 60–65%
V60 below 50–55%
V70 below 25–30%
Greco 2003 [38] 135 Median 28 
months
76Gy 6 field 3D-CRT RTOG ≥ Grad II 
late rectal 
toxicity
24 DVH from just below the 
sigmoid flexure to just 
above the anal verge
Cut-off:
V40 below 60%
V50 below 50%
V60 below 25%
V72 below 15%
V76 below 5%
Akimoto 2004 [39] 52 Median 31 
months
69Gy SD 
3Gy
unblocked 4 field 
technique to the 
prostate
RTOG ≥ Grad II 
late rectal 
toxicity
13 DVH above anal verge to 
point at which it turns 
into the sigmoid colon
Cut-off (equivalent 83Gy prescription 
dose):
V30 (V24.9) to ≥ 60%
V50 (V41.5) to ≥ 40%
V80 (V66.4) to ≥ 40%
V90 (V74.7) to ≥ 15%
Koper 2004 [40] 266 Minimum 2 
years
66Gy Conventional (n 
= 125) 3 field 
3D-CRT (n = 
123)
RTOG ≥ Grad I 
late rectal 
toxicity
57%
47%
DVH 
(separately 
for proximal, 
middle and 
distal part of 
rectum)
length of intestinal 
structures was limited to 
cranial and caudal field 
borders
Correlation with:
Distal rectal volume exposed to ≥ 
90% tumor dose
Lee 2005 [41] 212 Median 86 
months 35 
months
66 70 – 74Gy Conventional 
3D-CRT
Modified 
RTOG/Lent 
and RTOG
≥ Grad II 
late rectal 
toxicity
34 DVH ? Cut-offs:
≥ 60Gy to >51.5%
≥ 70Gy to >41.5%
Vargas 2005 [11] 331 Median 19 
months
70.2Gy to 
79.2Gy
Adaptive 3D-
CRT
CTC 2.0 ≥ Grad II 
late rectal 
toxicity
43 DVH, DWH from the anal verge or 
ischial tuberosities 
(whichever was higher) 
to the sacroiliac joints or 
rectosigmoid junction 
(whichever was lower)
Association with:
DWH: V50, V60, V66.6, V70, V72
DVH V60–V72
Peeters 2006 [42] 614 Median: 44 
months
68Gy vs 
78Gy
3D-CRT Adapted 
RTOG/
EORTC
≥ Grad II 
rectal 
bleeding
31 DWH anorectal, rectal, and 
anal wall dose volume 
histogram
Correlation with:
anorectal V55–V65
Table 2: Literature review of dose-volume relationship for late rectal bleeding in radiotherapy of prostate cancer (Continued)Radiation Oncology 2006, 1:34 http://www.ro-journal.com/content/1/1/34
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IMRT and 3D-CRT treatment planning. Because of signif-
icant differences between dose parameters and because
dose volume histograms do not provide spatial informa-
tion the importance of reviewing the dose distribution in
every single CT slice and not only relying on dose param-
eters has to be stressed.
Others studies compared rectal DVH, DWH and DSH in
treatment planning of the prostate [16-20]. Using a cylin-
drical model for the rectum Fiorino et al. described sub-
stantial differences between DVH and DWH for a "full"
rectum but only small differences for an "empty" rectum.
For patients with a distended rectum the DSH was close to
the DWH. Boehmer et al. [20] showed that the length of
delineating the rectum in superior-inferior direction sig-
nificantly influenced the dose to the rectum and therefore
should be standardized. However, all these studies are
based on 3D-CRT. In this work it has been clearly demon-
strated that a one-to-one transfer of the results from 3D-
CRT to IMRT treatment planning is not possible.
Another interesting result of this study was the finding
that the dose to the manually delineated rectal wall
(DWH) was different from the dose to the semi-automat-
ically generated rectal wall with 3 mm wall thickness
(DWH3). The choice of the 3-mm wall thickness is sup-
ported by the study of Rasmussen, in which the rectal wall
thickness measured by ultrasound was found to have a
median of 2.6 mm [21]. Tucker et al. reported only small
differences of the DWH for rectal wall thicknesses ranging
between 2 mm and 5 mm [19]. As the patients in this
study were treated in a supine position the intra-rectal
feces moved to the posterior rectal wall due to gravity.
With CT density values of the rectal wall often very similar
to the density of the filling a precise delineation of the
inner contour of the rectal wall was difficult for some
patients resulting in asymmetric rectal wall thicknesses
between anterior (within high-dose region) and posterior
(within mid- to low-dose region) rectal wall. It is likely
that this explains the differences between DWH3 and
DWH and because of this difficulty and uncertainty we do
not advocate delineating the inner contour of the rectum
manually. Though automatic generation of the DWH3
reduced uncertainties compared to DWH, the thickness of
the rectal wall is dependent on the rectal distension and
consequently not constant. Meijer et al. described a more
sophisticated method of automatic DWH generation [18]:
based on the delineated outer rectal contour the inner
contour was generated automatically taking the rectal dis-
tension into account.
Delineation of the outer contour of the rectum was found
to be associated with small intra- and inter-observer vari-
ability [22,23]. Consequently, in analysis of DVH and
DSH uncertainties are expected to be lower compared to
DWH analysis. Furthermore, generation of the DSH and
the DVH are known to be sensitive to parameters such as
voxel dimensions and dose calculation grid size [16].
These facts could partially be responsible for differences
between dose parameters.
Recently, de Crevoisier et al. showed an increased risk of
local failure and simultaneously a lower incidence of late
rectal bleeding for patients with a distended rectum on the
planning CT study [9]. Treatment planning based on a
planning CT with distended rectum introduced a system-
atic error with the prostate and the anterior rectal wall
moving posterior out of the high-dose-region during the
treatment. Repetition of the planning CT study in case of
a distended rectum was suggested to avoid this error.
Additionally, good agreement between DVH and DWH
was shown in case of an empty rectum making transfer of
constraints form the literature to treatment planning
more reliable.
The fact that one single planning CT study is only a snap-
shot of the patients' anatomy has to be considered for the
interpretation of dose-volume histograms. Image-guided
treatment techniques are thought to correct differences
between treatment planning and the current anatomy at
the time of treatment [24-27]. Recently, technologies
introduced 3D volume imaging into the treatment room
with sufficient soft-tissue contrast for visualization of the
prostate and OARs [28]. Such image-guided treatment
protocol are expected to allow a substantial reduction of
safety margins and consequence in a further escalation of
the treatment dose [25].
Comparison of 3D-CRT and IMRT in terms of sparing the
rectum was not aim of this study. A simultaneous inte-
grated boost concept was applied for the IMRT plans
whereas a homogenous dose distribution without field
size reduction was planned for the 3D-CRT plans. It was
interesting to note that the "benefit" of IMRT in compari-
son to 3D-CRT was strongly dependent on the way of con-
touring the rectum. Doses to the rectum were reduced in
the IMRT plan by 23%, 11% and 7% with the calculation
based on the rectal DVH, DWH3 and the DSH.
Conclusion
This study demonstrated that the method of delineating
the rectum significantly influenced the dose representa-
tion in external beam radiotherapy of localized prostate
cancer. Differences between the dose parameters, based
on delineation of the rectal wall, rectal volume and rectal
surface, were larger in IMRT treatment planning compared
with 3D-CRT. It was shown that the patient's anatomy,
both the rectal filling and the anatomy of the seminal ves-
icles, influenced the relationship between the four evalu-
ated parameters. For integration of dose-volumeRadiation Oncology 2006, 1:34 http://www.ro-journal.com/content/1/1/34
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parameters from the literature into treatment planning
these results have to be considered: a one-to-one transfer
of the results from 3D-CRT to IMRT treatment planning
may be associated with substantial errors.
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